Cosmos Health (COSM) Stock Forecast and Price Target (2026)

Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. That is the situation with COSM. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model rather than a consensus.

Figures are approximate and tied to the asOf date; verify live numbers before acting. Because Cosmos is lossmaking, price-to-earnings multiples do not apply, and at ~0.46x trailing sales the market values it mainly on revenue growth and the credibility of its 2026 and 2029 targets rather than current profit. With cash under $2 million and a sub-$1 share price facing a listing deadline, capital-structure, dilution and delisting risk matter more to the stock than any single quarter's sales.

For the fiscal year ending Dec 2026, the one analyst publishing estimates on COSM expects earnings of -$0.22 per share and revenue of $80.8 million (+24%).

Estimates are the most widely published forecast there is: many more analysts model a company's earnings than publish a price target on it. They are also revised constantly, and the direction of those revisions into a report is often more informative than the level.

Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering COSM do not put out a 2030 number. Anything presenting one is extrapolating a growth rate rather than reporting research, and a figure produced that way tells you about the assumption chosen, not about the company.

What can be said over a long horizon is what the current price already assumes about the business, which is a question the filings answer and a forecast cannot.

That is the more useful frame for a ten-year question. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Cosmos Health can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.

In short: the drivers cited most often are Revenue growth and 2029 targets, Branded products and margin mix, Geographic and channel expansion. The risk cited most often against it is the overriding risks are financial and structural rather than operational.

Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the COSM is it a buy page. This page deliberately stops at the numbers.